Newsletter Tool

Today’s Big News

Aug 20, 2024

Merck & Co. bags one Kelun ADC for $37.5M, boots out another asset as pipeline tinkering continues

Pathalys raises $105M series B to prepare Japan-approved kidney disease drug for FDA

Denmark's Adcendo signs $1B biobuck deal for Multitude’s anti-TF ADC

Talus Bio tacks on $11M to target hard-to-reach transcription factors

Avantor sells clinical services unit to private equity firm for $650M

Featured

Merck & Co. bags one Kelun ADC for $37.5M, boots out another asset as pipeline tinkering continues

By Nick Paul Taylor

Merck & Co. is continuing to tinker with its antibody-drug conjugate alliance with Kelun-Biotech, agreeing to pay $37.5 million to take up its option on one candidate while returning the rights to another asset.

Pathalys raises $105M series B to prepare Japan-approved kidney disease drug for FDA

By James Waldron

Pathalys Pharma has brought in $105 million via a series B fundraise that the kidney disease-focused biotech will use to take its lead candidate through the final stages of clinical development.

Denmark's Adcendo signs $1B biobuck deal for Multitude’s anti-TF ADC

By James Waldron

Denmark’s Adcendo is the latest biotech to go big in an antibody-drug conjugate (ADC) deal, signing off on $1 billion in biobucks to get the ex-China rights to a preclinical candidate from Multitude Therapeutics.

What’s Next for Biotech? Join Fierce Biotech Editors in Boston at Fierce Biotech Summit

Talus Bio tacks on $11M to target hard-to-reach transcription factors

By Gabrielle Masson

Seattle-based Talus Bioscience has raised $11.2 million in an early fundraising round, money that will go toward advancing the biotech’s portfolio of preclinical cancer programs and help build out the biotech’s drug discovery platform.

Avantor sells clinical services unit to private equity firm for $650M

By Gabrielle Masson

Biopharma supplier Avantor is offloading its clinical services unit to Audax Private Equity for $650 million.

Lilly adds to tirzepatide's impressive pedigree with new data showing the med helps stave off diabetes

By Fraiser Kansteiner

Already wildly popular in type 2 diabetes and obesity, Eli Lilly’s tirzepatide can help prevent one of the very diseases it’s meant to treat, new data show.

Medicare Advantage consensus waning ahead of 2024 election

By Noah Tong

Republicans and Democrats alike seem open to reforming Medicare Advantage, though cuts to the program earlier this year may have electoral consequences to Harris.

Targeting AZ's Tagrisso, Johnson & Johnson's Rybrevant combo wins key FDA nod in first-line lung cancer

By Angus Liu

A new FDA approval has vaulted a Johnson & Johnson lung cancer drug combination into a key territory already dominated by AstraZeneca’s Tagrisso. But the real battle against the EGFR king has yet to start.

Were industry watchers too optimistic after IRA's price cut reveal? Analysts weigh in

By Fraiser Kansteiner

The magnitude of price cuts under the Inflation Reduction Act initially appeared better than expected. However, that rosy view may have missed an important point, one analyst team contends.

Fierce podcasts

Don’t miss an episode

The TROP2 race for supremacy

In this week’s episode of “The Top Line,” Fierce executive editor Eric Sagonowsky chats with Angus Liu about his feature story on the three TROP2 front-runners.

What the data says about the telehealth market

A closer look at Fierce Biotech's Fierce 15

Resources

Whitepaper

Launching a Product in Europe: Understanding Supply Chain Cost Drivers

This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs.

Efficient-Pro Medium and Feed 1 enable rapid and seamless upstream process development and scale-up for CHO-K1 cells

Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale.

2024 Life Sciences Industry Outlook

The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond.